Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $183
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $182 to $183.
Stocks · News reference
RBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $198 Price Target
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $253
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
Neurocrine Biosciences has received FDA IND acceptance for a Phase 2 study of NBI-1117567, an oral muscarinic M1/M4 selective agonist for Alzheimer's cognition. Nxera Pharma will receive a $10 million milestone payment. This marks the third compound in Nxera's muscarinic agonist portfolio to advance to Phase 2, following direclidine in Phase 3 and NBI-1117570 in Phase 2.